Iovance Biotherapeutics (IOVA) Total Liabilities (2010 - 2026)
Iovance Biotherapeutics (IOVA) posted quarterly Total Liabilities of $203.9 million for Q1 2026, up 2.53% year-over-year from $198.9 million in Q1 2025, and down 4.98% quarter-over-quarter from $214.6 million in Q4 2025.
Iovance Biotherapeutics (IOVA) Total Liabilities (2010 - 2026) Analysis & Trends
Iovance Biotherapeutics (IOVA) has reported Total Liabilities for 17 consecutive years, with $203.9 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Total Liabilities rose 2.53% year-over-year to $203.9 million; the TTM figure through Mar 2026 stood at $203.9 million (up 2.53% YoY), while the FY2025 annual figure was $214.6 million, up 7.28% from the prior year.
- Total Liabilities slipped to $203.9 million in Q1 2026 per IOVA's latest filing, from $214.6 million in the prior quarter.
- Across five years, Total Liabilities topped out at $214.6 million in Q4 2025 and bottomed at $138.2 million in Q2 2022.
- Historically, Total Liabilities has averaged $182.2 million across 5 years, with a median of $189.8 million in 2024.
- Annual changes were most pronounced in 2022 — Total Liabilities surged 44.71% — and 2024, when it climbed 2.19%.
- Iovance Biotherapeutics' Total Liabilities stood at $164.3 million in 2022, then grew by 19.1% to $195.7 million in 2023, then grew by 2.19% to $200.0 million in 2024, then rose by 7.28% to $214.6 million in 2025, then retreated by 4.98% to $203.9 million in 2026.
- Business Quant data shows IOVA's Total Liabilities at $203.9 million in Q1 2026, $214.6 million in Q4 2025, and $202.7 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 7.18 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 10.02 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.62 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 1.72 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 4.00 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 7.02 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 10.03 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 4.20 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 1.35 Bn |
| 10 | Iovance Biotherapeutics | 3.16 Bn | 2.86 Bn | 55.72 Mn | 179.49 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 179.49 Mn |
| Mar 31, 2026 | 203.91 Mn |
| Dec 31, 2025 | 214.59 Mn |
| Sep 30, 2025 | 202.66 Mn |
| Jun 30, 2025 | 208.95 Mn |
| Mar 31, 2025 | 198.88 Mn |
| Dec 31, 2024 | 200.02 Mn |
| Mar 31, 2024 | 189.81 Mn |
| Dec 31, 2023 | 195.74 Mn |
| Sep 30, 2023 | 178.31 Mn |
| Jun 30, 2023 | 178.72 Mn |
| Mar 31, 2023 | 157.89 Mn |
| Dec 31, 2022 | 164.34 Mn |
| Sep 30, 2022 | 152.19 Mn |
| Jun 30, 2022 | 138.19 Mn |
| Mar 31, 2022 | 149.26 Mn |
| Dec 31, 2021 | 155.67 Mn |
| Sep 30, 2021 | 130.50 Mn |
| Jun 30, 2021 | 108.38 Mn |
| Mar 31, 2021 | 103.14 Mn |